Chapter 1. Research Framework

1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

Chapter 2. Research Methodology

2.1. Qualitative Research

2.1.1. Primary & Secondary Sources

2.2. Quantitative Research

2.2.1. Primary & Secondary Sources

2.3. Breakdown of Primary Research Respondents, By Region

2.4. Assumption for the Study

2.5. Market Size Estimation

2.6. Data Triangulation

Chapter 3. Executive Summary: Global Diagnostics Market

Chapter 4. Global Diagnostics Market Overview

4.1. Industry Value Chain Analysis

4.1.1. Material Provider

4.1.2. Manufacturer

4.1.3. Service Provider

4.1.4. End user

4.2. Diagnostics Industry Outlook

4.2.1. Global Epidemiology Data, by Disease

4.2.1.1. Tuberculosis

4.2.1.2. Asthma

4.2.1.3. Sepsis

4.2.1.4. Pneumonia

4.3. PESTLE Analysis

4.4. Porter's Five Forces Analysis

4.4.1. Bargaining Power of Suppliers

4.4.2. Bargaining Power of Buyers

4.4.3. Threat of Substitutes

4.4.4. Threat of New Entrants

4.4.5. Degree of Competition

4.5. Market Dynamics and Trends

4.5.1. Growth Drivers

4.5.2. Restraints

4.5.3. Challenges

4.5.4. Key Trends

4.6. Covid-19 Impact Assessment on Market Growth Trend

4.7. Market Growth and Outlook

4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2017 - 2030

4.7.2. Pricing Analysis

4.8. Competition Dashboard

4.8.1. Market Concentration Rate

4.8.2. Company Market Share Analysis (Value %), 2020

4.8.3. Competitor Mapping

Chapter 5. Tuberculosis Diagnostics Market Overview

5.1. Key Insights

5.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)

5.2.1. By Test Type

5.2.1.1. Radiographic Method

5.2.1.2. Cytokine Detection Assay

5.2.1.3. Nucleic Acid Testing

5.2.1.4. Detection of Latent Infection

5.2.1.5. Diagnostic Laboratory Method

5.2.1.6. Detection of Drug Resistance

5.2.1.7. Others

5.2.2. By End User

5.2.2.1. Clinics

5.2.2.2. Hospitals

5.2.2.3. Research Institutes & Academics

5.2.2.4. Reference Laboratories

5.2.3. By Key Players

5.2.3.1. Alere Inc.

5.2.3.2. F.Hoffmann-La Roche AG

5.2.3.3. Abbott Laboratories

5.2.3.4. Becton, Dickinson and Company

5.2.3.5. bioM?rieux SA

5.2.3.6. Siemens

5.2.3.7. Hologic Corporation

5.2.3.8. Cepheid

5.2.3.9. Hain Lifesciences GmbH

5.2.3.10. Thermo Fisher Scientific Inc.

5.2.4. By Region

5.2.4.1. North America

5.2.4.1.1. The U.S.

5.2.4.1.2. Canada

5.2.4.1.3. Mexico

5.2.4.2. Europe

5.2.4.2.1. Western Europe

5.2.4.2.1.1. The UK

5.2.4.2.1.2. Germany

5.2.4.2.1.3. France

5.2.4.2.1.4. Italy

5.2.4.2.1.5. Spain

5.2.4.2.1.6. Rest of Western Europe

5.2.4.2.2. Eastern Europe

5.2.4.2.2.1. Poland

5.2.4.2.2.2. Russia

5.2.4.2.2.3. Rest of Eastern Europe

5.2.4.3. Asia Pacific

5.2.4.3.1. China

5.2.4.3.2. India

5.2.4.3.3. Japan

5.2.4.3.4. Australia & New Zealand

5.2.4.3.5. ASEAN

5.2.4.3.6. Rest of Asia Pacific

5.2.4.4. Middle East & Africa (MEA)

5.2.4.4.1. UAE

5.2.4.4.2. Saudi Arabia

5.2.4.4.3. South Africa

5.2.4.4.4. Rest of MEA

5.2.4.5. South America

5.2.4.5.1. Brazil

5.2.4.5.2. Argentina

5.2.4.5.3. Rest of South America

Chapter 6. Asthma Diagnostics Market Overview

6.1. Key Insights

6.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)

6.2.1. By Test Type

6.2.1.1. Spirometry Test

6.2.1.2. Bronchodilator Reversibility Test

6.2.1.3. FeNO Test

6.2.1.4. Peak Flow

6.2.1.5. Bronchial Challenge Tests

6.2.1.6. Allergy tests

6.2.1.7. Others

6.2.2. By End User

6.2.2.1. Clinics

6.2.2.2. Hospitals

6.2.2.3. Research Institutes & Academics

6.2.2.4. Reference Laboratories

6.2.3. By Key Players

6.2.3.1. Becton, Dickinson and Company

6.2.3.2. Koninklijke Philips N.V.

6.2.3.3. ResMed

6.2.3.4. Fischer & Paykel

6.2.3.5. Others

6.2.4. By Region

6.2.4.1. North America

6.2.4.1.1. The U.S.

6.2.4.1.2. Canada

6.2.4.1.3. Mexico

6.2.4.2. Europe

6.2.4.2.1. Western Europe

6.2.4.2.1.1. The UK

6.2.4.2.1.2. Germany

6.2.4.2.1.3. France

6.2.4.2.1.4. Italy

6.2.4.2.1.5. Spain

6.2.4.2.1.6. Rest of Western Europe

6.2.4.2.2. Eastern Europe

6.2.4.2.2.1. Poland

6.2.4.2.2.2. Russia

6.2.4.2.2.3. Rest of Eastern Europe

6.2.4.3. Asia Pacific

6.2.4.3.1. China

6.2.4.3.2. India

6.2.4.3.3. Japan

6.2.4.3.4. Australia & New Zealand

6.2.4.3.5. ASEAN

6.2.4.3.6. Rest of Asia Pacific

6.2.4.4. Middle East & Africa (MEA)

6.2.4.4.1. UAE

6.2.4.4.2. Saudi Arabia

6.2.4.4.3. South Africa

6.2.4.4.4. Rest of MEA

6.2.4.5. South America

6.2.4.5.1. Brazil

6.2.4.5.2. Argentina

6.2.4.5.3. Rest of South America

Chapter 7. Sepsis Diagnostics Market Overview

7.1. Key Insights

7.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)

7.2.1. By Test Type

7.2.1.1. CRP Test

7.2.1.2. PT & PTT Test

7.2.1.3. Urinalysis

7.2.1.4. Pulse Oximetry

7.2.1.5. Others

7.2.2. By End User

7.2.2.1. Clinics

7.2.2.2. Hospitals

7.2.2.3. Research Institutes & Academics

7.2.2.4. Reference Laboratories

7.2.3. By Key Players

7.2.3.1. bioM?rieux

7.2.3.2. Becton Dickinson Company

7.2.3.3. Danaher

7.2.3.4. Abbott Laboratories

7.2.3.5. Roche Diagnostics

7.2.3.6. T2 Biosystems

7.2.3.7. Luminex

7.2.3.8. Others

7.2.4. By Region

7.2.4.1. North America

7.2.4.1.1. The U.S.

7.2.4.1.2. Canada

7.2.4.1.3. Mexico

7.2.4.2. Europe

7.2.4.2.1. Western Europe

7.2.4.2.1.1. The UK

7.2.4.2.1.2. Germany

7.2.4.2.1.3. France

7.2.4.2.1.4. Italy

7.2.4.2.1.5. Spain

7.2.4.2.1.6. Rest of Western Europe

7.2.4.2.2. Eastern Europe

7.2.4.2.2.1. Poland

7.2.4.2.2.2. Russia

7.2.4.2.2.3. Rest of Eastern Europe

7.2.4.3. Asia Pacific

7.2.4.3.1. China

7.2.4.3.2. India

7.2.4.3.3. Japan

7.2.4.3.4. Australia & New Zealand

7.2.4.3.5. ASEAN

7.2.4.3.6. Rest of Asia Pacific

7.2.4.4. Middle East & Africa (MEA)

7.2.4.4.1. UAE

7.2.4.4.2. Saudi Arabia

7.2.4.4.3. South Africa

7.2.4.4.4. Rest of MEA

7.2.4.5. South America

7.2.4.5.1. Brazil

7.2.4.5.2. Argentina

7.2.4.5.3. Rest of South America

Chapter 8. Pneumonia Diagnostics Market Overview

8.1. Key Insights

8.2. Market Size and Forecast, 2017 - 2030 (US$ Mn)

8.2.1. By Test Type

8.2.1.1. Blood Test

8.2.1.2. Chest X-Ray Test

8.2.1.3. Pulse Oximetry

8.2.1.4. Sputum Test

8.2.1.5. Others

8.2.2. By End User

8.2.2.1. Hospitals

8.2.2.2. Reference Laboratories

8.2.2.3. Homecare

8.2.2.4. Others

8.2.3. By Key Players

8.2.3.1. Thermo Fisher Scientific Inc.

8.2.3.2. Abbott Laboratories

8.2.3.3. F-Hoffmann la Roche Ltd.

8.2.3.4. Hologic Inc.

8.2.3.5. bioMerieux

8.2.3.6. Becton

8.2.3.7. Dickenson and Company

8.2.3.8. Bio-Rad Laboratories Inc.

8.2.3.9. Meridian Biosciences

8.2.3.10. Quest Diagnostics

8.2.3.11. Quidel

8.2.3.12. Others

8.2.4. By Region

8.2.4.1. North America

8.2.4.1.1. The U.S.

8.2.4.1.2. Canada

8.2.4.1.3. Mexico

8.2.4.2. Europe

8.2.4.2.1. Western Europe

8.2.4.2.1.1. The UK

8.2.4.2.1.2. Germany

8.2.4.2.1.3. France

8.2.4.2.1.4. Italy

8.2.4.2.1.5. Spain

8.2.4.2.1.6. Rest of Western Europe

8.2.4.2.2. Eastern Europe

8.2.4.2.2.1. Poland

8.2.4.2.2.2. Russia

8.2.4.2.2.3. Rest of Eastern Europe

8.2.4.3. Asia Pacific

8.2.4.3.1. China

8.2.4.3.2. India

8.2.4.3.3. Japan

8.2.4.3.4. Australia & New Zealand

8.2.4.3.5. ASEAN

8.2.4.3.6. Rest of Asia Pacific

8.2.4.4. Middle East & Africa (MEA)

8.2.4.4.1. UAE

8.2.4.4.2. Saudi Arabia

8.2.4.4.3. South Africa

8.2.4.4.4. Rest of MEA

8.2.4.5. South America

8.2.4.5.1. Brazil

8.2.4.5.2. Argentina

8.2.4.5.3. Rest of South America

Chapter 9. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, Measurement Methods and Business Strategy Outlook)

9.1. Abbott Laboratories

9.2. Alere Inc.

9.4. Becton, Dickinson and Company

9.5. bioM?rieux SA

9.6. Bio-Rad Laboratories Inc.

9.7. Cepheid

9.8. Danaher

9.9. F.Hoffmann-La Roche AG

9.10. Fischer & Paykel

9.1. Hain Lifesciences GmbH

9.11. Hologic Corporation

9.12. Koninklijke Philips N.V.

9.13. Luminex

9.14. Meridian Biosciences

9.15. Quest Diagnostics

9.16. Quidel

9.17. ResMed

9.18. Siemens

9.19. T2 Biosystems

9.20. Thermo Fisher Scientific Inc.